Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

ANNX - Annexon, Inc. Последние новости | Finranks

Home

/

ANNX

A

Annexon, Inc. (ANNX)

NMS – Цена в реальном времени. Валюта: USD

5.44

-0.24 (-4.23%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA

Annexon to Present at the Bank of America Securities Health Care Conference 2026

Annexon to Present at the Bank of America Securities Health Care Conference 2026

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., President and Chief Executive Officer, will present at the Bank of America Securities Health Care Conference 2026 on Wednesday, May 13, 2026 at 11:20 a.m. PT.

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq.

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?

The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Видео

No Data

There is no data to display

Пресс-релизы

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS

CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).